Plus Therapeutics, Inc.

PSTV

US72941H5090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-17 EDT			5-day change	1st Jan Change
2 ^USD	0.00%		-9.50%	+14.28%

06-07	Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024	CI
06-07	Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program	MT

Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024

June 07, 2024 at 04:02 pm

On June 5, 2024, Plus Therapeutics, Inc. received the resignation of Dr. Norman LaFrance, its Chief Medical Officer. Dr. LaFrance?s resignation is effective June 12, 2024.

Latest news about Plus Therapeutics, Inc.

Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024	06-07	CI
Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program	06-07	MT
Plus Therapeutics, Inc. Draws $3.3 Million on Its Existing Margin Loan Facility with Pershing Llc	06-04	CI
Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024	05-15
Plus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Transcript : Plus Therapeutics, Inc. - Special Call	05-09
Plus Therapeutics, Inc. acquired CNSide, a leptomeningeal metastases diagnostic platform.	05-08	CI
Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC	05-08	CI
Plus Therapeutics, Inc. announced that it expects to receive $6.548504 million in funding from Aigh Capital Management, LLC	05-04	CI
Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense	04-22	MT
Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense	04-22	CI
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	03-25	CI
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	03-11	CI
Transcript : Plus Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	03-05
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
North American Morning Briefing : S&P 500 Futures -2-	03-05	DJ
Transcript : Plus Therapeutics, Inc. - Special Call	11-20
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting	11-20	CI
Top Premarket Gainers	11-03	MT
Plus Therapeutics Shares Jump Premarket on FDA Orphan Designation	11-03	DJ
Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024	23-10-31	CI
Transcript : Plus Therapeutics, Inc., Q3 2023 Earnings Call, Oct 31, 2023	23-10-31
Plus Therapeutics, Inc. announces an Equity Buyback for $0.5 million worth of its shares.	23-10-31	CI
Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Plus Therapeutics, Inc. authorizes a Buyback Plan.	23-10-30	CI

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Plus Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2 USD

Average target price

19 USD

Spread / Average Target

+850.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PLUS THERAPEUTICS, INC.	+14.28%	11.41M
MODERNA, INC.	+38.66%	52.85B
IQVIA HOLDINGS INC.	-7.81%	38.87B
LONZA GROUP AG	+35.60%	38.24B
CELLTRION, INC.	-10.77%	26.79B
ICON PUBLIC LIMITED COMPANY	+11.77%	26.16B
ALNYLAM PHARMACEUTICALS, INC.	-17.82%	19.9B
UNITED THERAPEUTICS CORPORATION	+35.09%	13.18B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
BIO-TECHNE CORPORATION	-3.05%	11.79B

Other Biotechnology & Medical Research